Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
13.47
USD
|
-3.16%
|
|
-2.25%
|
-21.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,089
|
6,703
|
2,488
|
1,584
|
2,416
|
1,952
|
-
|
-
|
Enterprise Value (EV)
1 |
1,089
|
6,179
|
2,257
|
1,494
|
2,299
|
1,900
|
1,835
|
1,691
|
P/E ratio
|
-5.66
x
|
-21.5
x
|
-7.22
x
|
-8.1
x
|
190
x
|
-127
x
|
25.9
x
|
9.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7,164
x
|
44,097
x
|
372
x
|
569
x
|
10.3
x
|
7.29
x
|
4.69
x
|
3.3
x
|
EV / Revenue
|
7,164
x
|
40,652
x
|
337
x
|
536
x
|
9.84
x
|
7.1
x
|
4.41
x
|
2.86
x
|
EV / EBITDA
|
-
|
-
|
-6.55
x
|
-7.76
x
|
110
x
|
444
x
|
31.5
x
|
24.4
x
|
EV / FCF
|
-8.13
x
|
-28.8
x
|
-7.62
x
|
-8.48
x
|
-73.2
x
|
-808
x
|
11.8
x
|
5.17
x
|
FCF Yield
|
-12.3%
|
-3.48%
|
-13.1%
|
-11.8%
|
-1.37%
|
-0.12%
|
8.46%
|
19.3%
|
Price to Book
|
-
|
14.1
x
|
11.5
x
|
27.3
x
|
15.8
x
|
9.83
x
|
10.5
x
|
4.79
x
|
Nbr of stocks (in thousands)
|
98,104
|
128,848
|
130,950
|
133,915
|
141,455
|
144,904
|
-
|
-
|
Reference price
2 |
11.10
|
52.02
|
19.00
|
11.83
|
17.08
|
13.47
|
13.47
|
13.47
|
Announcement Date
|
3/2/20
|
3/1/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.152
|
0.152
|
6.689
|
2.785
|
233.7
|
267.6
|
416.4
|
591.8
|
EBITDA
1 |
-
|
-
|
-344.5
|
-192.5
|
20.84
|
4.283
|
58.21
|
69.39
|
EBIT
1 |
-169.1
|
-273.6
|
-344.8
|
-192.8
|
20.63
|
-11.44
|
82.41
|
223.2
|
Operating Margin
|
-111,220.39%
|
-179,996.05%
|
-5,154.28%
|
-6,924.2%
|
8.83%
|
-4.27%
|
19.79%
|
37.72%
|
Earnings before Tax (EBT)
1 |
-172.9
|
-279.4
|
-348.1
|
-198.3
|
13.06
|
-14.05
|
97.29
|
257.9
|
Net income
1 |
-172.9
|
-279.4
|
-348.1
|
-198.3
|
12.67
|
-14.41
|
83.03
|
216.7
|
Net margin
|
-113,730.92%
|
-183,803.29%
|
-5,204.08%
|
-7,121.54%
|
5.42%
|
-5.39%
|
19.94%
|
36.61%
|
EPS
2 |
-1.960
|
-2.420
|
-2.630
|
-1.460
|
0.0900
|
-0.1057
|
0.5200
|
1.355
|
Free Cash Flow
1 |
-133.9
|
-214.9
|
-296
|
-176.2
|
-31.41
|
-2.35
|
155.2
|
327
|
FCF margin
|
-88,097.37%
|
-141,357.89%
|
-4,425.7%
|
-6,326.18%
|
-13.44%
|
-0.88%
|
37.27%
|
55.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
266.63%
|
471.31%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
186.93%
|
150.94%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
2.03
|
2.321
|
2.016
|
0.594
|
0.094
|
0.08
|
7.803
|
16.07
|
165.8
|
43.97
|
54.58
|
56.89
|
66.31
|
78.79
|
EBITDA
1 |
-85.05
|
-92.87
|
-66.8
|
-38.86
|
-
|
-51.99
|
-36.92
|
-44.64
|
114.9
|
-12.45
|
-
|
-6
|
-5
|
3
|
EBIT
1 |
-85.13
|
-92.95
|
-66.87
|
-38.94
|
-34.96
|
-52.06
|
-36.99
|
-44.67
|
114.8
|
-12.48
|
-6.134
|
-9.597
|
-5.576
|
1.023
|
Operating Margin
|
-4,193.5%
|
-4,004.61%
|
-3,317.06%
|
-6,555.72%
|
-37,194.68%
|
-65,077.5%
|
-474.07%
|
-277.93%
|
69.22%
|
-28.39%
|
-11.24%
|
-16.87%
|
-8.41%
|
1.3%
|
Earnings before Tax (EBT)
1 |
-85.64
|
-93.34
|
-69.01
|
-40.51
|
-35.82
|
-52.99
|
-39.23
|
-47.61
|
113.9
|
-14.03
|
-4.31
|
-10.86
|
-3.745
|
0.1728
|
Net income
1 |
-85.64
|
-93.34
|
-69.01
|
-40.51
|
-35.82
|
-52.99
|
-39.23
|
-47.61
|
113.9
|
-14.42
|
-6.425
|
-10.86
|
-7.188
|
-0.303
|
Net margin
|
-4,218.57%
|
-4,021.46%
|
-3,423.26%
|
-6,819.87%
|
-38,104.26%
|
-66,242.5%
|
-502.78%
|
-296.19%
|
68.71%
|
-32.79%
|
-11.77%
|
-19.08%
|
-10.84%
|
-0.38%
|
EPS
2 |
-0.6500
|
-0.7000
|
-0.5100
|
-0.3000
|
-0.2600
|
-0.3900
|
-0.2800
|
-0.3400
|
0.7300
|
-0.1000
|
-0.0433
|
-0.0733
|
-0.0500
|
-0.005000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/1/22
|
5/10/22
|
8/8/22
|
11/9/22
|
2/28/23
|
5/1/23
|
8/1/23
|
11/1/23
|
2/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
524
|
231
|
90.5
|
117
|
51.9
|
116
|
261
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-134
|
-215
|
-296
|
-176
|
-31.4
|
-2.35
|
155
|
327
|
ROE (net income / shareholders' equity)
|
-
|
-100%
|
-92%
|
-134%
|
11.6%
|
6.55%
|
15.3%
|
54%
|
ROA (Net income/ Total Assets)
|
-
|
-70.8%
|
-69.3%
|
-69.2%
|
4.84%
|
-3%
|
7.2%
|
29.5%
|
Assets
1 |
-
|
394.3
|
502.6
|
286.6
|
261.6
|
480.4
|
1,153
|
734.5
|
Book Value Per Share
2 |
-
|
3.690
|
1.660
|
0.4300
|
1.080
|
1.370
|
1.280
|
2.810
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-1.300
|
-0.2100
|
-0.2400
|
0.8800
|
-
|
Capex
1 |
0.13
|
0.36
|
0.4
|
0.01
|
-
|
16.1
|
28.1
|
41.4
|
Capex / Sales
|
86.18%
|
234.87%
|
5.99%
|
0.5%
|
-
|
6%
|
6.75%
|
7%
|
Announcement Date
|
3/2/20
|
3/1/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
13.47
USD Average target price
29.75
USD Spread / Average Target +120.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.14% | 1.95B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|